New P2Y 12 inhibitors, such as prasugrel and ticagrelor, have favorable pharmacodynamics and clinical efficacy over clopidogrel and offer an alternative antiplatelet treatment strategy in specific ...

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic ...

When compared with clopidogrel, ticagrelor was associated with significant reductions in mortality among patients with acute coronary syndromes (ACS), without increasing the overall incidence of ...

Highlights include new evidence on intracoronary imaging and the first inclusion of a mechanical circulatory support device ...

It was a hugely complex operation with patients randomised to ticagrelor or clopidogrel in a double blind, double dummy test, taking either active ticagrelor or dummy ticagrelor or active clopidogrel ...

In order for ticagrelor to get approved, clinical trials had to prove that it was a better drug than competitors, like clopidogrel and prasugrel, in a phase 3 trial. After phase 3, the drug gets ...

In the UK, the National Institute for Health and Care Excellence (NICE) recommended in October 2011 that ticagrelor is a cost-effective and superior alternative to generic clopidogrel in patients with ...